Arbor Biotechnologies®, an early stage biodiscovery company, today announced it has strengthened its leadership team with the appointment of Daniel Maarten Janse as Chief Business Officer.
“Daniel’s strategic focus on business development and his extensive experience in early stage biodiscovery will be a tremendous asset to Arbor. We are delighted to have him join the team,” said Arbor Founder David Walt.
Daniel joins Arbor from Juno Therapeutics, where he was Senior Director, Business Development. He previously held leadership positions at Johnson & Johnson, Inventages Venture Capital, Cell Therapy Ltd., McKinsey and Co., and the Novartis Institutes for Biomedical Research.
Daniel holds a Ph.D. in Biological and Biomedical Sciences from Harvard University and a B.Sc. / B.A. with Honors in Biochemistry and Economics from Brown University. Arbor was co-founded in 2016 by David Scott, Winston Yan, Feng Zhang, and David Walt. The company closed its $15.6 million Series A financing in June 2017, and in March of this year, announced its discovery of the CRISPR Cas13d enzyme. The discovery was made utilizing Arbor’s proprietary platform which enables the high-throughput discovery and characterization of new proteins.
Arbor is making its discoveries available to the international research community and has contributed plasmids containing the Cas13d gene to Addgene’s repository. To further foster research and application development, the company will also make the enzymes available commercially via strategic partnerships. Interested organizations should contact email@example.com.